At Janssen, we are committed to helping people living with HIV in resource-limited settings by ensuring effective and sustainable access to our HIV medicines, or antiretrovirals (ARVs). We believe that effective HIV drug access has two important components: ensuring quality and affordable medicines are available sustainably and that they are used safely and in the most appropriate way for people living with HIV/AIDS (PLWHA).
Through our comprehensive HIV drug access framework (Read our Framework PDF), our Global Access and Partnerships Program (GAPP) works to fulfill our responsibility to provide access to our medicines, specifically in least-developed countries and lower middle-income countries (LDCs and LMICs). The program includes:
- Operating on a sustainable, not-for-profit basis in LDCs and LMICs (Read our Special Access Pricing for Branded HIV Medicines PDF)
- Licensing for both branded and generic versions of our HIV medicines (Read our Licensing PDF)
- Prioritizing regulatory filings where there is a public health need (Read our Branded Registration Efforts PDF)
- Supporting the optimal, appropriate and safe use of our HIV medicines (Read our Optimizing Use of Our HIV Medicines in Resource-Limited Countries PDF)
We invite you to learn more by viewing the Janssen Global Access & Partnerships Program Overview: HIV Medicine Access brochure (PDF).